Evidence map›Paper›PMID 36160021›Full record

ArticleFrontiers in genetics2022

Comparison of effectiveness and safety of camrelizumab between HBV-related and non-B, non-C hepatocellular carcinoma: A retrospective study in China.

Haonan Liu, Xiaobing Qin, Zhiyuan Xu, Meng Wu, Tong Lu, Shuang Zhou, Nan Yao, Suya Liu, Yong Shao, Zhengxiang Han

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Haonan LiuDepartment of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Xiaobing QinDepartment of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Zhiyuan XuDepartment of Emergency, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Meng WuDepartment of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Tong LuDepartment of Gastroenterology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Shuang ZhouDepartment of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Nan YaoDepartment of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Suya LiuDepartment of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Yong ShaoDepartment of General Surgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Zhengxiang HanDepartment of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

camrelizumabeffectivenesshepatitis B virushepatocellular carcinomaimmunotherapysafety

Identifiers

PMID36160021
PMCPMC9500546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.